StockData
Celldex Therapeutics, Inc. logo

Celldex Therapeutics, Inc. (CLDX) income statement

CLDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$27.42−0.54 (-1.93%)

Close on Nov 20, 2026Market cap $2.15BP/E –Yield –

See a number that looks wrong?